Vivoryon Therapeutics Résultats passés
Passé contrôle des critères 0/6
Vivoryon Therapeutics's earnings have been declining at an average annual rate of -26.2%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 17.4% per year.
Informations clés
-26.2%
Taux de croissance des bénéfices
-13.2%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 11.5% |
| Taux de croissance des recettes | -17.4% |
| Rendement des fonds propres | -223.1% |
| Marge nette | 861.5% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Ventilation des recettes et des dépenses
Comment Vivoryon Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | -4 | -31 | 7 | 22 |
| 31 Mar 24 | -4 | -30 | 8 | 20 |
| 31 Dec 23 | -4 | -28 | 8 | 18 |
| 30 Sep 23 | -2 | -27 | 10 | 17 |
| 30 Jun 23 | 0 | -26 | 11 | 15 |
| 31 Mar 23 | 0 | -27 | 10 | 18 |
| 31 Dec 22 | 0 | -28 | 9 | 20 |
| 30 Sep 22 | 0 | -26 | 7 | 20 |
| 30 Jun 22 | 11 | -14 | 5 | 19 |
| 31 Mar 22 | 11 | -13 | 5 | 18 |
| 31 Dec 21 | 11 | -13 | 5 | 17 |
| 30 Sep 21 | 11 | -12 | 4 | 17 |
| 30 Jun 21 | 0 | -21 | 4 | 16 |
| 31 Mar 21 | 0 | -19 | 3 | 15 |
| 31 Dec 20 | 0 | -17 | 3 | 13 |
| 30 Sep 20 | 0 | -15 | 3 | 11 |
| 30 Jun 20 | 0 | -12 | 3 | 9 |
| 31 Mar 20 | 0 | -10 | 3 | 7 |
| 31 Dec 19 | 0 | -8 | 3 | 5 |
| 30 Sep 19 | 0 | -7 | 3 | 4 |
| 30 Jun 19 | 0 | -7 | 3 | 4 |
| 31 Mar 19 | 0 | -7 | 3 | 4 |
| 31 Dec 18 | 0 | -8 | 3 | 5 |
| 30 Sep 18 | 0 | -8 | 3 | 5 |
| 30 Jun 18 | 0 | -8 | 3 | 5 |
| 31 Mar 18 | 0 | -8 | 3 | 6 |
| 31 Dec 17 | 0 | -8 | 3 | 7 |
| 30 Sep 17 | 0 | -10 | 3 | 9 |
| 30 Jun 17 | 0 | -12 | 3 | 11 |
| 31 Mar 17 | 0 | -13 | 3 | 11 |
| 31 Dec 16 | 0 | -14 | 3 | 11 |
| 30 Sep 16 | 0 | -14 | 3 | 11 |
| 30 Jun 16 | 0 | -13 | 3 | 10 |
| 31 Mar 16 | 0 | -13 | 3 | 10 |
| 31 Dec 15 | 0 | -14 | 3 | 10 |
| 30 Sep 15 | 0 | -14 | 4 | 10 |
| 30 Jun 15 | 0 | -14 | 4 | 10 |
| 31 Mar 15 | 0 | -13 | 4 | 9 |
| 31 Dec 14 | 0 | -11 | 3 | 8 |
| 30 Sep 14 | 0 | -10 | 3 | 8 |
| 30 Jun 14 | 0 | -9 | 2 | 7 |
| 31 Mar 14 | 0 | -9 | 2 | 8 |
Des revenus de qualité: VVYA is currently unprofitable.
Augmentation de la marge bénéficiaire: VVYA is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: VVYA is unprofitable, and losses have increased over the past 5 years at a rate of 26.2% per year.
Accélération de la croissance: Unable to compare VVYA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: VVYA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Rendement des fonds propres
ROE élevé: VVYA has a negative Return on Equity (-223.07%), as it is currently unprofitable.